Jennifer Brown

Worthington and Margaret Collette Professor of Medicine

Dana-Farber Cancer Institute
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (73)

Pirtobrutinib, a noncovalent, reversible Bruton tyrosine kinase inhibitor (BTKi), demonstrated efficacy in patients with chronic lymphocytic leukemia (CLL), resistant to covalent BTKi (cBTKi). We analyzed genomic correlations with response and resistance to pirtobrutinib in relapsed/refractory (R/R) patients with CLL pretreated with cBTKi enrolled in the phase 1/2 BRUIN trial. DNA sequencing was performed on peripheral blood mononuclear cells at baseline, on treatment, and at progressive disease (PD). Common alterations at baseline included mutations in BTK (43%), TP53 (38%), SF3B1 (25%), NOTCH1 (23%), ATM (19%), XPO1 (11%), PLCG2 (9%), BCL2 (8%), and 17p deletion (28%). Common baseline BTK mutations included C481S (85%), C481R (10%), C481F (6%), and C481Y (4%). At PD, 60 of 88 patients (68%) acquired ≥1 mutation, including 44% with acquired BTK mutations and 24% with other acquired mutations. A total of 55 acquired BTK mutations were detected in 39 patients, including gatekeeper mutations (T474I/F/S/Y/L, 26%), kinase-impaired L528W (16%), C481S/R/Y (5%), V416L (2%), and A428D (1%) and others proximal to the adenosine triphosphate–binding pocket, D539A/G/H (1%) and Y545N (1%). Decrease or complete clearance of BTK C481x was observed at PD in 36 of 43 patients (84%). Using a more sensitive assay, 37% (18/49) of acquired BTK mutations were detected at baseline at low allele frequency. Using a highly sensitive assay at progression, a similar frequency of acquired BTK mutations (39%) was detected, and all patients had detectable acquired mutations. This study highlights the complex clonal dynamics of BTK mutations in patients with R/R CLL undergoing pirtobrutinib treatment, and the extent of resistance without an obvious genomic driver. Trial registration: #NCT03740529 at www.ClinicalTrials.gov.

Year:

2026

Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.

Year:

2025

Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.

Year:

2025

Purpose: The management of chronic lymphocytic leukemia (CLL) has significantly improved with targeted therapies. However, many patients experience a suboptimal response. To optimally select the best therapy, predictive biomarkers are necessary. In this study, we used the phosphoinositide 3-kinase (PI3K) inhibitor umbralisib as a model to (i) understand the impact of targeted treatment on cell signaling and immunophenotypes in responders and nonresponders, (ii) identify molecular features that predict individual treatment responses, and (iii) suggest alternative treatment options for the nonresponders. Experimental Design: We performed functional phenotyping of CLL cells from patients enrolled in two clinical trials with umbralisib, administered either as a monotherapy (NCT02742090, n = 55) or in combination with the Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (NCT04624633, n = 12). Results: We found that umbralisib monotherapy led to significant changes in (phospho)protein levels, including AKT (pS473), in responders but not in nonresponders. Furthermore, the proportion of cytotoxic natural killer (NK) cells increased at the end of the study but only in responders, suggesting a role in the antitumor response. To identify molecular predictors of response, we used the baseline levels of 30 (phospho)proteins in the monotherapy cohort as input features for a machine learning model, which achieved significant prediction accuracy in cross-validation and maintained its predictive power in the combination cohort. Drug sensitivity profiling of the CLL cells at baseline suggested that PI3K + Bcl-2 inhibitors are effective in umbralisib nonresponders. Conclusions: Functional phenotyping reveals differential cellular responses to umbralisib treatment in responders and nonresponders; predicts treatment response of individual patients with CLL; and suggests alternative treatment options for the nonresponders.

Year:

2025

We analyzed the characteristics and outcomes of 95 patients with chronic lymphocytic leukemia (CLL) after Bruton tyrosine kinase inhibitor (BTKi) and B-cell lymphoma 2 inhibitor (BCL2i) failure. To clearly distinguish sensitivity and resistance to the targeted treatment classes, we defined double refractory (DR) CLL when progressive disease occurred during active treatment with a BTKi and a BCL2i, given sequentially or in combination, and double exposed (DE) disease when treatment with either or both of these agents was discontinued due to reasons other than progression. Thirty patients (31.6%) had DR CLL, and 65 (63.2%) had DE CLL. The DR group more frequently had unmutated immunoglobulin gene heavy chain variable (97%), TP53 aberration (73%), and BTK mutations (59%) than the DE group (75%, 46%, and 27%, respectively). The median number of total lines of therapy was 6 for DR and 3 for DE. Nearly all DR patients (97%) required subsequent therapy after developing DR CLL. The most commonly used treatment was noncovalent BTKis (34%), followed by concurrent covalent BTKi and BCL2i (28%) and CD19 chimeric antigen receptor-modified T cells (24%). Treatment for DE CLL was less frequently observed (26%). The median overall survival (OS) was 2.2 years once DR developed, despite the frequent initial responses to noncovalent BTKis or cellular therapy in the cohort. Patients with DE CLL demonstrated favorable survival (median OS not reached) and durable response to subsequent therapy.

Year:

2025

Multi-omics analyses. Output tables of the moderated t-tests comparing transcriptome, microRNA and methylation profiles of resistant and parental. Output results of Gene Set Enrichment Analysis comparing GEP data of resistant and parental.

Year:

2025

Levels of p-AKT (A, top) and p-ERK (B, bottom) were determined by phospho-flow cytometry upon 1µM of idelalisib. Density plots show the median MFI values of two replicates, negative control (dotted black), parental (grey), resistant (red). (B) Images on the left show the expression of pRELA by immunofluorescence upon 1µM of idelalisib (right) or control (DMSO, left) in parental and resistant (4hr exposure). Boxplot on the right represents the protein quantification from the immunofluorescence experiments. Data derived from two independent experiments. Three representative fields were evaluated from each independent experiment. P-values from Welch Two Sample test performed on mean MFI values.

Year:

2025

Cell viability was evaluated by MTT assay (72h). Karpas1718 parental (A) or resistant (B) were exposed to DMSO (control, black) or decitabine (100nM, red), given concomitantly (continuous lines) or 72 hours before idelalisib (pre DMSO in dashed black or pre decitabine in dashed red). Error bars correspond to standard deviation of the mean. Data derived from two independent experiments. Statistically significant differences were evaluated by moderated t-test comparing each treatment to control (DMSO).

Year:

2025

Ridgeplot on surface levels of ERBB4 by FACS in Karpas1718 resistant cells upon genetic silencing (siRNA) of ERBB2 (yellow), ERBB4 (red) or concomitant ERBB2 and ERBB4 (brown). Silencing control in grey and negative control in black. Data derived from two independent experiments. Statistically significant differences (p

Year:

2025

(A) Immunoblotting was performed to measure protein levels in parental and resistant clones for pAKT/AKT and pERK/ERK in three independent experiments. GAPDH was used as a loading control. (B) Protein quantification was done normalizing first to GAPDH and then to total protein. Barplot represents the quantification in each of the independent experiments, parental in grey, resistant in red. Median and standard error of the mean for parental and resistant levels in the three experiments. Moderated t-test was performed to determine statistically significance (p

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (34)

ANASTASIOS STATHIS

Head of Research Service and Scientific Head Clinical Trial Unit

Istituto Cantonale di Patologia

SWITZERLAND
View details

Stefano Vergani

Lund University

SWEDEN
View details

Jianjun Chen

Director

Beckman Research Institute, City of Hope

UNITED STATES
View details

Martin Šimkovič

Fakultní Nemocnice Hradec Králové

CZECH REPUBLIC
View details

FRANCO FAIS

University of Genoa

ITALY
View details

Chan Yoon Cheah

University of Western Australia

AUSTRALIA
View details

Jingyi Jessica Li

Professor and Program Head

Fred Hutch Cancer Center

UNITED STATES
View details

Xinzhou Ge

Assistant professor

Oregon State University

UNITED STATES
View details

Constantine S. Tam

-

AUSTRALIA
View details

Andrea Nicola Mazzarello

Assistant Professor

University of Genoa

ITALY
View details

Mazyar Shadman

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Robert Weinkove

Clinical Director

Malaghan Institute of Medical Research

NEW ZEALAND
View details

Toby A. Eyre

-

UNITED KINGDOM
View details

Giulio Sartori

Università della Svizzera Italiana (USI)

SWITZERLAND
View details

Emanuele Zucca

University of Bern

SWITZERLAND
View details

Adam Olszewski

Associate Professor of Medicine

Rhode Island Hospital

UNITED STATES
View details

Tero Aittokallio

Group Leader

University of Helsinki

FINLAND
View details

Jennifer A. Woyach

-

UNITED STATES
View details

Sara Napoli

National Institute of Oncology

SWITZERLAND
View details

Sigrid S. Skånland

Senior Researcher and Lab Leader

Oslo University Hospital

NORWAY
View details

Steven Rosen

Provost & Chief Scientific Officer

City of Hope

UNITED STATES
View details

Nicholas Chiorazzi

Professor and Center Head

Feinstein Institute for Medical Research

UNITED STATES
View details

Afua Adjeiwaa Mensah

-

SWITZERLAND
View details

Tadeusz Robak

Professor

Medical University of Lodz

POLAND
View details

Joe-Elie Salem

Professor of Medicine and Pharmacology

Assistance Publique - Hôpitaux de Paris

FRANCE
View details

Steven Allen

Associate Chief, Division Of Hematology

Northwell Health

UNITED STATES
View details

Davide Rossi

Associate Professor of Medicine

Università della Svizzera Italiana (USI)

SWITZERLAND
View details

Yanping Yin

Oslo University Hospital

NORWAY
View details

Paolo Ghia

-

ITALY
View details

Manel Esteller

Group Leader, Cancer Epigenetics Group

Josep Carreras Leukaemia Research Institute

SPAIN
View details

Markus Kalkum

Professor

Beckman Research Institute, City of Hope

UNITED STATES
View details

Tanya Siddiqi

Associate Professor

City Of Hope National Medical Center

UNITED STATES
View details

Nirav N. Shah

Medical College of Wisconsin

UNITED STATES
View details

Manuel Castro de Moura

Head of Bioinformatics Unit

Josep Carreras Leukaemia Research Institute

SPAIN
View details